Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 7;14(24):6023.
doi: 10.3390/cancers14246023.

Immunohistochemical Markers of the Epithelial-to-Mesenchymal Transition (EMT) Are Related to Extensive Lymph Nodal Spread, Peritoneal Dissemination, and Poor Prognosis in the Microsatellite-Stable Diffuse Histotype of Gastric Cancer

Affiliations

Immunohistochemical Markers of the Epithelial-to-Mesenchymal Transition (EMT) Are Related to Extensive Lymph Nodal Spread, Peritoneal Dissemination, and Poor Prognosis in the Microsatellite-Stable Diffuse Histotype of Gastric Cancer

Daniele Marrelli et al. Cancers (Basel). .

Abstract

Background: Although the prognostic value of the epithelial-to-mesenchymal transition (EMT) in gastric cancer has been reported in several studies, the strong association with the diffuse type may represent a confounding factor. Our aim is to investigate potential correlations among EMT status, tumor advancement, and prognosis in diffuse gastric cancer. Methods: Between 1997 and 2012, 84 patients with microsatellite-stable (MSS) diffuse-type tumors underwent surgery. The EMT phenotype was assessed with the E-cadherin, CD44, and zinc finger E-box binding homeobox 1 (ZEB-1) immunohistochemical markers. Results: Forty-five out of 84 cases (54%) were EMT-positive; more advanced nodal status (p = 0.010), pTNM stage (p = 0.032), and vascular invasion (p = 0.037) were observed in this group. The median numbers of positive nodes (13 vs. 5) and involved nodal stations (4 vs. 2) were higher in the EMT-positive group. The cancer-related survival time was 26 months in EMT-positive cases vs. 51 in negative cases, with five-year survival rates of 17% vs. 51%, respectively (p = 0.001). The EMT status had an impact on the prognosis of patients with <70 years, R0 resections, or treatment with adjuvant chemotherapy. Tumor relapses after surgery and peritoneal spread were significantly higher in the EMT-positive tumors. Conclusions: EMT status, when assessed through immunohistochemistry, identified an aggressive phenotype of MSS diffuse-type tumors with extensive lymph nodal spread, peritoneal dissemination, and worse long-term outcomes.

Keywords: diffuse histotype; epithelial-to-mesenchymal transition; gastric cancer; immunohistochemistry; microsatellite-stable tumors; outcome; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative samples of positivity for epithelial-to-mesenchymal transition markers: (a) A poorly cohesive signet ring cell phenotype (acc. to WHO) or diffuse type (acc. to Lauren) infiltrating the muscular layer is presented; (b) a 8/18 cytokeratin stain confirming the epithelial origin of the neoplastic proliferation is shown; (c) E-cadherin negativity of neoplastic cells is depicted; the positive control is represented by the normal gastric epithelium on the right side expressing E-cadherin; (d) neoplastic cells show membranous positivity for CD44 and nuclear expression of Zeb-1 (inset, bottom right) in more than 10% of cells. (a) Hematoxylin and eosin; (b) CK8/18 stain; (c) E-cadherin stain; (d) CD44 stain; inset on the bottom right, Zeb-1 stain. Original magnification (OM): (ad), 4×; (d), inset, 10×.
Figure 2
Figure 2
Representative sample of negativity for epithelial-to-mesenchymal transition markers: (a) A poorly cohesive other cell type (WHO) or diffuse type (Lauren) is presented; (b) a 8/18 cytokeratin stain confirming the epithelial origin of the neoplastic proliferation is shown; (c) E-cadherin positivity of neoplastic cells is depicted; (d) neoplastic cells do not show positivity for CD44 and Zeb-1 (inset, bottom right); the positive control is represented by lymphocytes (arrows). (a) Hematoxylin and eosin; (b) CK8/18 stain; (c) E-cadherin stain; (d) CD44 stain; inset on the bottom right, Zeb-1 stain. Original magnification (OM): (ad), 4×; (d), inset, 10×.
Figure 3
Figure 3
(a) Box-plot representation of the correlation between EMT status and the number of positive lymph nodes (Mann–Whitney U-test). The box represents the interquartile range (IQR), which contains 50% of the values; the lines extending from the box indicate the highest and lowest non-outlier values, while the line across the box indicates the median value. Circles represent “mild” outliers, i.e., values between 1.5 and 3.0 times the IQR; asterisks represent “extreme” outliers, i.e., values more than 3.0 times the IQR. (b) Box-plot representation of the correlation between EMT status and the number of metastatic lymph nodal stations classified according to the JGCA guidelines (Mann–Whitney U-test). A median number of 10 lymph node stations for patients were removed (range 6 to 15); a total number of 924 lymph node stations were analyzed. (c) Linear correlation between the number of removed and positive lymph nodes in EMT-positive and EMT-negative cases.
Figure 4
Figure 4
Cancer-specific survival according to EMT status in MSS diffuse-type tumors; the difference is statistically significant (Log-rank test).
Figure 5
Figure 5
Cancer-specific survival according to EMT status: (a) MSS diffuse-type tumors that did not involve the serosa and (b) MSS diffuse-type tumors that involved the serosa; stratified for age groups: (c) <70 years old and (d) ≥70 years old (Log-rank test).

Similar articles

Cited by

References

    1. Marrelli D., Pedrazzani C., Morgagni P., De Manzoni G., Pacelli F., Coniglio A., Marchet A., Saragoni L., Giacopuzzi S., Roviello F. Changing clinical and pathological features of gastric cancer over time. Br. J. Surg. 2011;98:1273–1283. doi: 10.1002/bjs.7528. - DOI - PubMed
    1. Koemans W.J., Lurvink R.J., Grootscholten C., Verhoeven R.H.A., de Hingh I.H., van Sandick J.W. Synchronous peritoneal metastases of gastric cancer origin: Incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24:800–809. doi: 10.1007/s10120-021-01160-1. - DOI - PubMed
    1. Roviello F., Marrelli D., De Manzoni G., Morgagni P., Di Leo A., Saragoni L., De Stefano A. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br. J. Surg. 2003;90:1113–1119. doi: 10.1002/bjs.4164. - DOI - PubMed
    1. Marrelli D., Polom K., Neri A., Roviello F. Clinical impact of molecular classifications in gastric cancer. Updat. Surg. 2018;70:225–232. doi: 10.1007/s13304-018-0546-0. - DOI - PubMed
    1. Marrelli D., Morgagni P., De Manzoni G., Marchet A., Baiocchi G.L., Giacopuzzi S., Coniglio A., Mocellin S., Saragoni L., Roviello F. External Validation of a Score Predictive of Recurrence after Radical Surgery for Non-Cardia Gastric Cancer: Results of a Follow-Up Study. J. Am. Coll. Surg. 2015;221:280–290. doi: 10.1016/j.jamcollsurg.2015.03.042. - DOI - PubMed